Zobrazeno 1 - 3
of 3
pro vyhledávání: '"William Charles Penley"'
Autor:
Patrick Murphy, Lowell L. Hart, Adil Moyhuddin, Jeffrey Patton, Dana S. Thompson, Suzanne F. Jones, Chris Earwood, Jeffrey R. Infante, Shubham Pant, Johanna C. Bendell, William Charles Penley, Cassie M. Lane
Publikováno v:
Cancer Investigation. 33:477-482
Background: This phase I study determined the maximum tolerated dose (MTD) of AUY922 with capecitabine in advanced solid tumors. Methods: Capecitabine 1000mg/m2 PO BID was administered with escalating doses of AUY922 IV; the MTD of AUY922 was combine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::522d00ebf1128ee0f4191dcdeae22ebd
https://doi.org/10.3109/07357907.2015.1069834
https://doi.org/10.3109/07357907.2015.1069834
Autor:
Dana S. Thompson, Dianna Shipley, Charles D. Webb, John D. Hainsworth, William Charles Penley, David M. Waterhouse, F. Anthony Greco
Publikováno v:
Cancer Investigation. 31:323-329
Purpose: To evaluate the feasibility and efficacy of sorafenib and everolimus in renal cell carcinoma (RCC). Methods: Patients with advanced RCC and ≤1 previous targeted therapy were treated. Results: Maximum tolerated doses were sorafenib 200 mg P
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::64de48a4f2aa772db3ba2a2ff9683652
https://doi.org/10.3109/07357907.2013.789900
https://doi.org/10.3109/07357907.2013.789900
Autor:
F. A. Greco, David M. Waterhouse, John D. Hainsworth, William Charles Penley, Charles D. Webb, H. A. Burris
Publikováno v:
Journal of Clinical Oncology. 29:4629-4629
4629 Background: Sorafenib and everolimus are standard agents with different targets (VEGFR and m-TOR, respectively) for the treatment of advanced RCC. Combined use of these agents may improve efficacy. This phase I/II trial established the maximum t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1fa3c7d0c526e8d23999c83c69b59192
https://doi.org/10.1200/jco.2011.29.15_suppl.4629
https://doi.org/10.1200/jco.2011.29.15_suppl.4629